RESUMO
Given that von Willebrand disease (VWD) is one of the most common bleeding disorders, the diagnosis or the exclusion is essential in the workup of individuals that have unexplained bleeding. For the clinical laboratory, the challenge is highlighted by the variable presentations of this disorder and the multiple assays that are available from different vendors. This review will give a brief overview of primary hemostasis with a detailed explanation of the biosynthesis, structure, and mechanics of von Willebrand factor (VWF). The final sections will focus on the distinguishing characteristics of the different types of VWD and the array of clinical laboratory tests currently available to assist in the diagnosis.
Assuntos
Doenças de von Willebrand , Fator de von Willebrand , Hemostasia , Humanos , Doenças de von Willebrand/diagnósticoRESUMO
Autosomal dominant Beta Thalassemias are rare and are due to point or frame shift mutations resulting in production of abnormal unstable beta chains of hemoglobin which precipitate leading to hemolysis and anemia. We describe a case of Hemoglobin Hakkari, a rare variant of dominant Thalassemia arising due to a de novo mutation in the exon 2 of the beta globin gene.
Assuntos
Hemoglobinas Anormais/genética , Talassemia beta/genética , Pré-Escolar , Éxons , Feminino , Humanos , Mutação , Globinas beta/genética , Talassemia beta/sangueRESUMO
Hb Youngstown is a rare hemoglobin (Hb) variant caused by substitution of glutamic acid with alanine at amino acid residue 101 of the ß-globin chain as a result of an A > C transversion on the ß-globin gene nucleotide sequences [ß101(G3)Glu â Ala; HBB: c.305A > C]. We now report three patients from two different families, one from South Africa and the other from Costa Rica, who are heterozygous for this Hb variant. All three carriers had marked hemolysis, consistent with Hb Youngstown being a highly unstable variant. The substitution of glutamic acid, a large and negatively charged amino acid, with alanine, a small and non polar amino acid, in the interface of the α1- and ß2-globin subunits might interfere with the transition between the oxy- and deoxyHb, and lead to Hb instability and hemolytic anemia.
Assuntos
Anemia Hemolítica Congênita/genética , Hemoglobinas Anormais/genética , Mutação de Sentido Incorreto , Adulto , Substituição de Aminoácidos , Anemia Hemolítica Congênita/diagnóstico , Anemia Hemolítica Congênita/patologia , Criança , Feminino , Humanos , Estabilidade ProteicaRESUMO
Iron is one of the most important nonorganic substances that make life possible. Iron plays major roles in oxygen transport (eg, hemoglobin; -67% of total body iron [TBI]), short-term oxygen storage (eg, myoglobin; -3.5% of TBI), and energy generation (eg, cytochromes; -3% of TBI). Iron also serves vital roles in various nonheme-containing enzymes (-2% of TBI). Figure 1 lists heme-containing and nonheme iron-containing proteins. TBI is controlled by the rate of iron absorption; there are no physiologic mechanisms to excrete excess iron. Iron deficiency has many adverse consequences, including anemia, and in children, behavioral and learning disorders. Iron excess is toxic to the body, harming the heart, liver, skin, pancreatic islet beta cells, bones, joints, and pituitary gland. Maintaining proper iron balance is essential for maintaining homeostasis and health. TBI in adults normally ranges between 3.5 and 5.0 g. A total of 75% of TBI is functional, and 25% is stored within cells as ferritin or hemosiderin. Ferritin contains 24 subunits of light chains (L chains; 19.7 kDa) and heavy chains (H chains; 21.1 kDa). The L chains are encoded on chromosome 19q13.33 and are 175 amino acids long. The H chains are encoded on chromosome 11q1 and are 183 amino acids long. Each ferritin molecule can contain as many as approximately 4500 ferric ions. Because the major role of iron is in hemoglobin synthesis, this review will focus on iron, iron transport, and hematopoiesis.
Assuntos
Anemia Ferropriva/metabolismo , Hematopoese/fisiologia , Sobrecarga de Ferro/metabolismo , Ferro/metabolismo , Anemia Ferropriva/genética , Anemia Ferropriva/patologia , Proteínas de Transporte de Cátions/genética , Proteínas de Transporte de Cátions/metabolismo , Ferritinas/genética , Ferritinas/metabolismo , Regulação da Expressão Gênica , Hemoglobinas/genética , Hemoglobinas/metabolismo , Hemossiderina/genética , Hemossiderina/metabolismo , Hepcidinas/genética , Hepcidinas/metabolismo , Homeostase/fisiologia , Humanos , Sobrecarga de Ferro/genética , Sobrecarga de Ferro/patologia , Mioglobina/genética , Mioglobina/metabolismo , Subunidades Proteicas/genética , Subunidades Proteicas/metabolismo , Receptores da Transferrina/genética , Receptores da Transferrina/metabolismo , Transferrina/genética , Transferrina/metabolismoRESUMO
OBJECTIVE: About 3% of patients with lupus develop severe diffuse alveolar hemorrhage (DAH) with pulmonary vasculitis. C57BL/6 (B6) mice with pristane-induced lupus also develop DAH, but BALB/c mice are resistant. DAH is independent of Toll-like receptor signaling and other inflammatory pathways. This study examined the role of the MEK1/2 pathway (MEK1/2-ERK1/2, JNK, p38). METHODS: B6 and BALB/c mice were treated with pristane with or without inhibitors of MEK1/2 (trametinib/GSK1120212 [GSK]), ERK1/2 (SCH772984 [SCH]), JNK, or p38. Effects on lung hemorrhage and hemostasis were determined. RESULTS: GSK and SCH abolished DAH, whereas JNK and p38 inhibitors were ineffective. Apoptotic cells were present in lung samples from pristane-treated mice but not in mice receiving pristane and GSK, and endothelial dysfunction was normalized. Expression of the ERK1/2-regulated transcription factor early growth response 1 increased in pristane-treated B6, but not BALB/c, mice and was normalized by GSK. Pristane also increased expression of the anticoagulant genes Tfpi and Thbd in B6 mice. The ratio of Tfpi to tissue factor (F3) to Tfpi increased in B6 (but not BALB/c) mice and was normalized by GSK. Circulating thrombomodulin protein levels increased in B6 mice and returned to normal after GSK treatment. Consistent with augmented endothelial anticoagulant activity, pristane treatment increased tail bleeding in B6 mice. CONCLUSION: Pristane treatment promotes lung endothelial injury and DAH in B6 mice by activating the MEK1/2-ERK1/2 pathway and impairing hemostasis. The hereditary factors determining susceptibility to lung injury and bleeding in pristane-induced lupus are relevant to the pathophysiology of life-threatening DAH in systemic lupus erythematosus and may help to optimize therapy.
RESUMO
Objective: About 3% of lupus patients develop severe diffuse alveolar hemorrhage (DAH) with pulmonary vasculitis. B6 mice with pristane-induced lupus also develop DAH, but BALB/c mice are resistant. DAH is independent of TLR signaling and other inflammatory pathways. This study examined the role of the mitogen-activated protein kinase pathway (MEK1/2-ERK1/2, JNK, p38). Methods: B6 and BALB/c mice were treated with pristane ± inhibitors of MEK1/2 (trametinib/GSK1120212, "GSK"), ERK1/2 (SCH772984, "SCH"), JNK, or p38. Effects on lung hemorrhage and hemostasis were determined. Results: GSK and SCH abolished DAH, whereas JNK and p38 inhibitors were ineffective. Apoptotic cells were present in lung from pristane-treated mice, but not mice receiving pristane+GSK and endothelial dysfunction was normalized. Expression of the ERK1/2-regulated transcription factor Egr1 increased in pristane-treated B6, but not BALB/c, mice and was normalized by GSK. Pristane also increased expression of the anticoagulant genes Tfpi (tissue factor pathway inhibitor) and Thbd (thrombomodulin) in B6 mice. The ratio of tissue factor ( F3 ) to Tfpi increased in B6 (but not BALB/c) mice and was normalized by GSK. Circulating Thbd protein increased in B6 mice and returned to normal after GSK treatment. Consistent with augmented endothelial anticoagulant activity, pristane treatment increased tail bleeding in B6 mice. Conclusion: Pristane treatment promotes lung endothelial injury and DAH in B6 mice by activating the MEK1/2-ERK1/2 pathway and impairing hemostasis. The hereditary factors determining susceptibility to lung injury and bleeding in pristane-induced lupus are relevant to the pathophysiology of life-threatening DAH in SLE and may help to optimize therapy.
RESUMO
BACKGROUND: The most ordered laboratory test worldwide is the complete blood count (CBC). CONTENT: In this primer, an introduction to platelet testing in the context of the CBC is provided with a discussion of the laboratory evaluation of platelet abnormalities including thrombocytopenia and thrombocytosis. SUMMARY: As clinical chemists continue to be tasked to direct laboratories outside of the traditional clinical chemistry sections such as hematology, expertise must be developed. This primer is dedicated to that effort.
Assuntos
Plaquetas , Trombocitopenia , Trombocitose , Humanos , Trombocitose/sangue , Trombocitose/diagnóstico , Trombocitopenia/diagnóstico , Trombocitopenia/sangue , Contagem de Plaquetas/métodos , Contagem de Células Sanguíneas/métodos , Contagem de Células Sanguíneas/instrumentação , Química Clínica/métodos , Química Clínica/normasRESUMO
BACKGROUND: The most frequently ordered laboratory test worldwide is the complete blood count (CBC). CONTENT: In this primer, the red blood cell test components of the CBC are introduced, followed by a discussion of the laboratory evaluation of anemia and polycythemia. SUMMARY: As clinical chemists are increasingly tasked to direct laboratories outside of the traditional clinical chemistry sections such as hematology, expertise must be developed. This review article is a dedication to that effort.
RESUMO
Hemoglobin A1c (HbA1c) refers to non-enzymatically glycated hemoglobin and reflects the patient's glycemic status over approximately 3 months. An elevated HbA1c over 6.5% National Glycohemoglobin Standardization Program (NGSP) (48 mmol/mol the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)) can be used to diagnose diabetes mellitus. In our laboratory, HbA1c is determined by ion-exchange chromatography which has the advantage of detecting common Hb variants such as Hb S, C, E and D without adversely affecting the HbA1c determination. Certain homozygous or compound heterozygous hemoglobinopathies such as homozygous sickle disease and Hb SC disease can significantly lower the HbA1c by reducing red cell lifespan. Occasionally however, rare and mostly benign hemoglobinopathies can interfere with this technique resulting in an apparent elevation of HbA1c in an otherwise non-diabetic patient. In this report, we describe such a hemoglobinopathy termed Hb Wayne that resulted in a significant HbA1c elevation in a normoglycemic individual. HbA1c was determined by multiple methods including immunoassay, a modified capillary electrophoresis and an alternative ion-exchange system. These techniques yielded significantly lower A1c results, more in keeping with the patient's clinical background. The alternative ion-exchange system resulted in a low A1c that was qualified by warning flags on the chromatogram that indicated the result was not reportable. The hemoglobinopathy in question, Hb Wayne, is a frameshift mutation in the alpha globin gene that results in an extended alpha globin polypeptide that can form two variants Hb Wayne I and Wayne II. Hb Wayne is a clinically silent asymptomatic disorder with no hematologic consequences. The artifactual elevation of HbA1c is, in contrast, very significant because it may result in a misdiagnosis of diabetes mellitus leading to unnecessary treatment. In this report, we compare our findings with other descriptions of Hb Wayne in the literature and corroborate a number of previous observations and conclusions.
RESUMO
OBJECTIVE: Andexanet alfa is a targeted reversal agent for life threatening hemorrhage associated with direct acting oral anticoagulants (DOACs), but there is uncertainty regarding the benefit when compared to 4-factor prothrombin complex concentrate (4F-PCC) for this indication. We investigated the clinical outcomes and cost associated with reversal of DOACs in the setting of life-threatening intracranial hemorrhage (ICH). METHODS: A retrospective evaluation was conducted to evaluate patients with ICH in the setting of anticoagulation with DOAC from 9/1/2013 to 4/30/2020. Patients were included in the study if they received reversal with either andexanet alfa or 4F-PCC. RESULTS: Eighty-nine patients were included in the study. There was no statistically significant difference in 30-day mortality between patients who received andexanet alfa or 4F-PCC (52% vs. 35%, P â=â0.14). Radiographic stability of bleed was identified in 57% of patients receiving andexanet alfa vs. 58% of patients receiving 4F-PCC ( P â=â0.93). Median length of stay was not different between the andexanet alfa and 4F-PCC populations (7âdays [IQR 6 - 12] vs. 6âdays [IQR 3-12], P â=â0.66). Median cost of reversal agent was higher in patients receiving andexanet alfa compared to 4F-PCC ($15 000 [IQR 15 000-$27 000] vs. $11 650 [IQR $8567-$14 149]). CONCLUSION: Among patients with life-threatening intracranial hemorrhage in the setting of DOAC therapy, no clinical differences were observed with respect to selection of reversal agent. Prothrombin complex concentrates remain a viable alternative to reversal of DOAC therapy though multicenter, randomized, prospective studies are needed to further evaluate the role of 4F-PCC in the reversal of DOAC therapy.
Assuntos
Anticoagulantes , Fatores de Coagulação Sanguínea , Fator Xa , Hemorragias Intracranianas , Proteínas Recombinantes , Humanos , Anticoagulantes/uso terapêutico , Fator IX/uso terapêutico , Hemorragia/tratamento farmacológico , Hemorragias Intracranianas/tratamento farmacológico , Estudos RetrospectivosRESUMO
BACKGROUND: Concentrations of cadmium (Cd) in the grain of many durum wheats (Triticum turgidum subsp. durum) grown in North American prairie soils often exceed international trade standards. Genotypic differences in root-to-shoot translocation of Cd are a major determinant of intraspecific variation in the accumulation of Cd in grain. We tested the extent to which changes in whole-plant Cd accumulation and the distribution of Cd between tissues influences Cd accumulation in grain by measuring Cd accumulation throughout the grain filling period in two near-isogenic lines (NILs) of durum wheat that differ in grain Cd accumulation. RESULTS: Roots absorbed Cd and transported it to the shoots throughout the grain filling period, but the low- and high-Cd NILs did not differ in whole-plant Cd uptake. Although the majority of Cd accumulation was retained in the roots, the low- and high-Cd NILs differed substantively in root-to-shoot translocation of Cd. At grain maturity, accumulation of Cd in the shoots was 13% (low-Cd NIL) or 37% (high-Cd NIL) of whole-plant Cd accumulation. Accumulation of Cd in all shoot tissue, including grain, was at least 2-fold greater in the high-Cd NIL at all harvests. There was no net remobilization of shoot Cd pools during grain filling. The timing of Cd accumulation in grain was positively correlated with grain biomass accumulation, and the rate of grain filling peaked between 14 and 28 days post-anthesis, when both NILs accumulated 60% of total grain biomass and 61-66% of total grain Cd content. CONCLUSIONS: These results show that genotypic variation in root-to-shoot translocation of Cd controls accumulation of Cd in durum wheat grain. Continued uptake of Cd by roots and the absence of net remobilization of Cd from leaves during grain filling support a direct pathway of Cd transport from roots to grain via xylem-to-phloem transfer in the stem.
Assuntos
Cádmio/metabolismo , Sementes/metabolismo , Triticum/metabolismo , Transporte Biológico , Genótipo , Raízes de Plantas/genética , Raízes de Plantas/crescimento & desenvolvimento , Raízes de Plantas/metabolismo , Brotos de Planta/genética , Brotos de Planta/crescimento & desenvolvimento , Brotos de Planta/metabolismo , Sementes/genética , Sementes/crescimento & desenvolvimento , Triticum/genética , Triticum/crescimento & desenvolvimentoRESUMO
Iron serves a critical role in many metabolic processes, including oxygen delivery (e.g., hemoglobin) and oxygen utilization for the generation of ATP (e.g., cytochromes). Disorders of iron metabolism are best recognized and evaluated in the context of iron's absorption, transportation, monitoring, cellular uptake, and recycling. This review highlights these processes so that disorders of iron deficiency and iron excess can be better understood. Key players in iron metabolism will be highlighted, such as hepcidin, ferroportin, erythroferrone, transferrin, ferritin, HFE, and the transferrin receptors.
Assuntos
Sobrecarga de Ferro , Ferro , Humanos , Ferro/metabolismo , Hepcidinas , Transferrina , Receptores da Transferrina/metabolismo , Oxigênio/metabolismo , BiologiaRESUMO
In hematology and coagulation, diligence in the preanalytical phase of testing is of critical importance to obtaining reliable test results. If the sample used for testing is unsuitable, even outstanding analytical procedures and technology cannot produce a clinically-reliable result. Therefore, the intent of this manuscript is to review preanalytical factors intrinsic to the sample that affect the hematology and coagulation testing. Factors intrinsic to the sample (excluding in vivo anomalies) can be controlled, theoretically, by phlebotomists (including nurses) and laboratorians in the preanalytical phase of testing. Furthermore, the management and prevention of such factors is highlighted. Erroneous control of preanalytical factors can produce laboratory errors.
Assuntos
Coagulação Sanguínea , Hematologia , Humanos , LaboratóriosRESUMO
Inherited dysfibrinogenemias are molecular disorders of fibrinogen that affect fibrin polymerization. The majority of cases are asymptomatic, but a significant proportion suffer from increased bleeding or thrombosis. We present two unrelated cases of dysfibrinogenemia, both of whom showed a characteristic discrepancy between fibrinogen activity and the immunologic fibrinogen. In one patient, the dysfibrinogenemia was confirmed by molecular analysis; in the other case, the diagnosis was presumptive based upon laboratory studies. Both patients underwent elective surgery. Both received a highly purified fibrinogen concentrate preoperatively and demonstrated a suboptimal laboratory response to the infusion. Three methods for determining fibrinogen concentration (Clauss fibrinogen, prothrombin-derived fibrinogen, and the viscoelastic functional fibrinogen) were utilized in the case of one patient, and these techniques showed discrepant results with the classic Clauss method giving the lowest concentration. Neither patient experienced excessive bleeding during surgery. Although these discrepancies have been previously described in untreated patients, their manifestation after infusion of purified fibrinogen is less well appreciated.
Assuntos
Afibrinogenemia , Hemostáticos , Trombose , Humanos , Fibrinogênio/uso terapêutico , Fibrinogênio/análise , Afibrinogenemia/diagnóstico , Hemorragia/etiologiaRESUMO
BACKGROUND: Point-of-care (POC) devices measuring hematocrit rely on determination of electrical conductivity of whole blood. We hypothesized that some frequently administered IV fluids independently alter blood conductivity and confound hematocrit determination. METHODS: Whole human blood was diluted to predetermined hematocrit values with normal saline, lactated Ringer solution, hetastarch, or plasma. Electrical conductivity and hematocrit (i-STAT® and spun methods) were measured at each dilution. In separate experiments, the effects of propofol and heparin were noted on these variables. RESULTS: Greater dilution significantly increased conductivity irrespective of diluent type. The magnitude of the conductivity slopes increased in order for plasma, hetastarch, lactated Ringer solution, and normal saline dilution. Moreover, each slope varied from every other slope (all P < 0.0001), and 94.2% of hematocrit values measured by i-STAT (n = 211 of 224) were less than those for the spun method. Dilution with plasma, normal saline, lactated Ringer solution, and hetastarch caused bias (Bland-Altman limits of agreement) of -2.7% (-6.9/1.4), -4.6% (-7.3/-2.0), -4.8% (-7.8/-1.7), and -2.0% (-5.6/1.9), respectively. The Cohen κ agreement values (5th-95th confidence interval) for a transfusion trigger of 30% were 0.90 (all values, 0.85-0.95), 0.25 (hematocrit <30%, 0.02-0.48), and 0.21 (hematocrit 18%-30%, 0.01-0.42). Clinically relevant concentrations of propofol and heparin had minimal effects on electrical conductivity or hematocrit determination. CONCLUSIONS: Dilution of blood with frequently used IV solutions affects whole blood conductivity determinations and thereby decreases hematocrits measured by a POC device relying on this method as compared with spun hematocrit. Conductivity-based hematocrit POC devices should be cautiously interpreted when hemodilution is present.
Assuntos
Hidratação/efeitos adversos , Hematócrito/instrumentação , Hemodiluição/efeitos adversos , Sistemas Automatizados de Assistência Junto ao Leito , Soluções para Reidratação/efeitos adversos , Viés , Condutividade Elétrica , Desenho de Equipamento , Heparina/farmacologia , Humanos , Derivados de Hidroxietil Amido/efeitos adversos , Soluções Isotônicas/efeitos adversos , Plasma , Valor Preditivo dos Testes , Propofol/farmacologia , Reprodutibilidade dos Testes , Lactato de Ringer , Cloreto de Sódio/efeitos adversosRESUMO
Congenital hemophilia B is a rare, inherited X-linked bleeding disorder caused by a deficiency of factor IX (FIX). Acquired hemophilia A is a rare, acquired bleeding disorder which presents as new onset bleeding in older adults due to the development of autoantibodies against factor VIII (FVIII). This report describes the management of a patient with congenital hemophilia B and acquired hemophilia A. We highlight the limitations in maintaining FVIII levels using factor replacement alone and the need for escalating treatment such as rituximab and prednisone in patients with acquired hemophilia A. This case demonstrates the importance of continuing to pursue alternative diagnoses when existing ones do not explain the full clinical picture and laboratory data is inconclusive.
RESUMO
CONTEXT.: Assessing direct oral anticoagulant (DOAC) drug levels by reliable laboratory assays is necessary in a number of clinical scenarios. OBJECTIVE.: To evaluate the performance of DOAC-specific assays for various concentrations of dabigatran and rivaroxaban, assess the interlaboratory variability in measurement of these DOACs, and investigate the responsiveness of the routine clotting assays to various concentrations of these oral anticoagulants. DESIGN.: College of American Pathologists proficiency testing survey data from 2013 to 2016 were summarized and analyzed. RESULTS.: For dabigatran, the interlaboratory coefficient of variation (CV) of ecarin chromogenic assay was broad (ranging from 7.5% to 29.1%, 6.3% to 15.5%, and 6.8% to 9.0% for 100-ng/mL, 200-ng/mL, and 400-ng/mL targeted drug concentrations, respectively). The CV for diluted thrombin time for dabigatran was better overall (ranging from 11.6% to 17.2%, 9.3% to 12.3, and 7.1% to 11.2% for 100 ng/mL, 200 ng/mL, and 400 ng/mL, respectively). The rivaroxaban-calibrated anti-Xa assay CVs also showed variability (ranging from 11.5% to 22.2%, 7.2% to 10.9%, and 6.4% to 8.1% for 50-ng/mL, 200-ng/mL, and 400-ng/mL targeted drug concentrations, respectively). The prothrombin time (PT) and activated partial thromboplastin time (aPTT) showed variable dose- and reagent-dependent responsiveness to DOACs: PT was more responsive to rivaroxaban and aPTT to dabigatran. The undiluted thrombin time showed maximum prolongation across all 3 dabigatran concentrations, making it too sensitive for drug-level monitoring, but supporting its use as a qualitative screening assay. CONCLUSIONS.: DOAC-specific assays performed reasonably well. While PT and aPTT cannot be used safely to determine DOAC degree of anticoagulation, a normal thrombin time excludes the presence of dabigatran.